<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04193137</url>
  </required_header>
  <id_info>
    <org_study_id>OSL-study 2019</org_study_id>
    <nct_id>NCT04193137</nct_id>
  </id_info>
  <brief_title>Comparison of Three Confirmatory Tests in the Diagnosis of Primary Aldosteronism</brief_title>
  <official_title>Comparison of Saline Infusion Test, Captopril Challenge Test, and Oral Sodium Loading Test in the Diagnosis of Primary Aldosteronism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the diagnostic value of three confirmatory tests for primary aldosteronism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study involving 240 hypertensive patients who underwent primary
      aldosteronism screening. Every patient will undertake four confirmatory tests to compare the
      diagnostic accuracy of the oral sodium loading test with captopril challenge testing (CCT)
      and Seated saline infusion test(SSST)using the fludrocortisone suppression testing (FST) as
      the reference standard, and to investigate the optimal cutoff of oral sodium loading test
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic Accuracy of oral sodium loading test, captopril challenge test and saline infusion test</measure>
    <time_frame>9 days</time_frame>
    <description>sensitivity, specificity and area under curve (AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the optimal cutoff value of urine aldosterone in oral sodium test</measure>
    <time_frame>3 days</time_frame>
    <description>urine aldosterone</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Primary Aldosteronism</condition>
  <arm_group>
    <arm_group_label>Primary Aldosteronism(PA)</arm_group_label>
    <description>plasma aldosterone /renin ratio (ARR)&gt;10 pg/μIU and plasma aldosterone concentration(PAC) post-FST≥60pg/ml；or PAC＞200 pg/ml，plasma renin concentration(PRC)＜2.5μIU/ml，with hypokalemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non Primary Aldosteronism</arm_group_label>
    <description>ARR&lt;10 pg/μIU or ARR&gt;10 pg/μIU and PAC post FST&lt;60pg/ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Oral sodium loading test,Seated saline infusion test and Captopril challenge test</intervention_name>
    <description>Oral sodium loading test : Patients received 6g oral sodium every day for 3 days.
Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.
Captopril challenge test: Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 2 h. Blood samples were drawn at time zero and 2 h after the challenge.</description>
    <arm_group_label>Primary Aldosteronism(PA)</arm_group_label>
    <arm_group_label>non Primary Aldosteronism</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma and complete blood cell. 24-h urine, etc
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        hypertensive patients being suspicious of PA in a single tertiary hospital center
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. hypertensive patients with ARR≥10(pg/ml)(uIU/ml)

          2. hypertensive patients with ARR＜10(pg/ml)(uIU/ml) but suspicious of PA clinically

        Exclusion Criteria:

          1. Pregnancy or lactation;

          2. Child-bearing women refuse to take effective contraceptive measures;

          3. History of malignant tumor;

          4. Patients with cardiovascular and cerebrovascular diseases (eg. myocardial infarction,
             acute heart failure, stroke), in the past 3 months

          5. NYHA III (New York Heart Association)and above

          6. Hypohepatia

          7. Chronic kidney disease with an estimated Glomerular Filtration Rate &lt;30ml/min/1.73 m²

          8. Severe arrhythmia by ECG or severe heart disease by cardiac ultrasound

          9. Patients who are unwilling to participate in and complete this study and refuses to
             sign the informed consent form for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qifu Li, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>the Chongqing Primary Aldosteronism Study (CONPASS) Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qifu Li, PhD</last_name>
    <phone>+86 023-89011552</phone>
    <email>liqifu@yeah.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qifu Li</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qifu Li, PhD</last_name>
      <phone>+86 23 89011552</phone>
      <email>liqifu@yeah.net</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916. doi: 10.1210/jc.2015-4061. Epub 2016 Mar 2.</citation>
    <PMID>26934393</PMID>
  </results_reference>
  <results_reference>
    <citation>Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019 Feb;285(2):126-148. doi: 10.1111/joim.12831. Epub 2018 Sep 25. Review.</citation>
    <PMID>30255616</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu S, Yang J, Hu J, Song Y, He W, Yang S, Luo R, Li Q. Confirmatory tests for the diagnosis of primary aldosteronism: A systematic review and meta-analysis. Clin Endocrinol (Oxf). 2019 May;90(5):641-648. doi: 10.1111/cen.13943. Epub 2019 Feb 26.</citation>
    <PMID>30721529</PMID>
  </results_reference>
  <results_reference>
    <citation>Mulatero P, Milan A, Fallo F, Regolisti G, Pizzolo F, Fardella C, Mosso L, Marafetti L, Veglio F, Maccario M. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab. 2006 Jul;91(7):2618-23. Epub 2006 May 2.</citation>
    <PMID>16670162</PMID>
  </results_reference>
  <results_reference>
    <citation>Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, Tanabe A; Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society. Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. Endocr J. 2011;58(9):711-21. Epub 2011 Aug 9.</citation>
    <PMID>21828936</PMID>
  </results_reference>
  <results_reference>
    <citation>Mulatero P, Monticone S, Burrello J, Veglio F, Williams TA, Funder J. Guidelines for primary aldosteronism: uptake by primary care physicians in Europe. J Hypertens. 2016 Nov;34(11):2253-7. doi: 10.1097/HJH.0000000000001088.</citation>
    <PMID>27607462</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 8, 2019</study_first_submitted>
  <study_first_submitted_qc>December 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Qifu Li</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <keyword>primary aldosteronism,</keyword>
  <keyword>oral sodium loading test</keyword>
  <keyword>captopril challenge test,</keyword>
  <keyword>Saline infusion test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Captopril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

